In this article Millennium Pharmaceuticals, Inc. informs about the approval from the U.S. Food and Drug Administration FDA to market VELCADE for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The effectiveness of VELCADE is...
In this article Millennium Pharmaceuticals, Inc. reveals that the U.S. Food and Drug Administration FDA accepted for review and granted Priority Review designation of the Company's New Drug Application NDA for VELCADE for the treatment of relapsed and refractory multiple myeloma. Priority Review is granted by the FDA to an...
In this article Millennium Pharmaceuticals, Inc. informs that it has submitted a complete Marketing Authorization Application MAA to the European Agency for the Evaluation of Medicinal Products EMEA for the approval of bortezomib VELCADE as a treatment for relapsed and refractory multiple myeloma. This application was submitted approximately one week...
In this article Millennium Pharmaceuticals, Inc. informs that it has submitted a New Drug Application NDA with the U.S. Food and Drug Administration FDA for approval to market VELCADE as a treatment for relapsed and refractory multiple myeloma. In June 2002, VELCADE was granted fast-track status by the FDA as...
This article focuses on VELCADE which is a novel drug candidate that may have broad applications in cancer. In January 2003, Millennium submitted a New Drug Application NDA to the U.S. Food and Drug Administration FDA for approval to market VELCADE as a treatment for relapsed and refractory multiple myeloma....
In this article Millennium Pharmaceuticals, Inc. informs that the U.S. Food and Drug Administration FDA accepted for review the Company's supplemental New Drug Application sNDA and granted Priority Review designation for VELCADE for the treatment of patients with multiple myeloma who have received at least one prior therapy. The submission...
This article discusses the Millennium Pharmaceuticals, Inc. approval from the U.S. Food and Drug Administration FDA to market VELCADE for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The effectiveness of VELCADE is based on...
In this article Millennium Pharmaceuticals, Inc. informs that the Company intends to file a New Drug Application NDA with the U.S. Food and Drug Administration FDA to market VELCADE as a treatment for relapsed and refractory multiple myeloma by early 2003. Earlier this year, VELCADE was granted fast-track status by...
With AT&T Tech Support 360, you'll have certified, U.S. based technicians on call 24/7 to help keep your computers, connections, software and peripherals up to speed for just 82¢ a day.
